| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |